tirzepatide 5.0 mg Unlikely to Exacerbate DR in First Year of Treatment Lilly launches lower-price weight-loss drug

These negative results may be due to limitations imposed by protein overexpression or reflect TMEM55Bs primary role in regulating TBC1D9B function, for example, by conformationally activating TBC1D9B to facilitate its catalytic activity

Both are dominated by gastrointestinal adverse events nausea, constipation, diarrhea, vomiting that are mostly mild-to-moderate and dose-related

Extended gaps mean medication levels have dropped substantially

Everyone in this study also had established cardiovascular disease, so I would not assume the same size of benefit in people with diabetes who do not already have heart problems